Extracorporeal photopheresis: Past, present, and future - 07/08/11
, Mark L. Barr, MD e, Daniel R. Couriel, MD f, James L.M. Ferrara, MD g, Lars E. French, MD h, Peter Jaksch, MD b, Walter Reinisch, MD c, Alain H. Rook, MD i, Thomas Schwarz, MD j, Hildegard Greinix, MD d
Reprint requests: Robert Knobler, MD, Division of Special and Environmental Dermatology, Department of Dermatology, Medical University of Vienna, Währingergürtel 18-20, A 1090 Vienna, Austria.Abstract |
Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological agents, ECP is an established and effective therapy for advanced cutaneous T-cell lymphoma. ECP has also shown promising efficacy in a number of other severe and difficult-to-treat conditions, including systemic sclerosis, graft-versus-host disease, prevention and treatment of rejection in solid organ transplantation, and Crohn disease. Furthermore, the use of ECP in some of these conditions may allow a significant reduction in the use of systemic steroids and other immunosuppressants, reducing long-term morbidity and mortality. The accumulated experience shows ECP to be well tolerated, with no clinically significant side effects. Progress is also being made in the search for understanding of the mechanisms of action of ECP, which will ultimately facilitate improvements in the use of this therapy.
Le texte complet de cet article est disponible en PDF.Key words : extracorporeal photopheresis, cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, systemic sclerosis, graft-versus-host disease, solid organ transplant, cardiac transplant, lung transplant, bronchiolitis obliterans, bronchiolitis obliterans syndrome, liver transplant, renal transplant, Crohn disease, atopic dermatitis, lichen planus, contact hypersensitivity mouse model, T-cell clonality, bone marrow transplant
Abbreviations used : BMT, BO, BO(S), CD, CHS, CR, CTCL, DNFB, ECP, GVHD, MF, MOP, PUVA, SS, TNF, UV
Plan
| Supported by an unrestricted educational grant from Therakos. |
|
| Disclosure: Dr Knobler is a consultant, investigator, and speaker for Therakos. Dr Couriel is on the Advisory Board for Genzyme; is an investigator for Genzyme, Cephalon, and Astellas; and a speaker for Therakos, Schering Plough, Pfizer, Genzyme, Astellas, and Kirin. Dr Ferrara is a consultant for Therakos. Dr Jaksch is a speaker for Therakos. Dr Reinisch is a consultant, investigator, and speaker for Therakos. Dr Rook is a consultant for Merck and Graceway, and a speaker for Therakos and Eisai. Dr Schwarz is on the Advisory Board for Therakos, Novartis, Agiderm, Abbott, Intendis, Allmiral, and Genmab and a stockholder of Agiderm. Dr Greinix is on the Advisory Board and an investigator and speaker for Therakos. Drs Barr and French have no conflicts of interest to declare. |
|
| This article was prepared by Ann McIlhinney, DPhil, of Anagram Communications Ltd, funded by Therakos, on behalf of the authors and is based on the presentations at a symposium held in the Vienna General Hospital of the Medical University of Vienna in 2007. |
Vol 61 - N° 4
P. 652-665 - octobre 2009 Retour au numéro
Article précédent
- Primary cutaneous cribriform apocrine carcinoma: A clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm
- Arno Rütten, Heinz Kutzner, Thomas Mentzel, Markus Hantschke, Fritof Eckert, Jorge Angulo, Jose Luis Rodríguez Peralto, Luis Requena
- Volunteers Needed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?